An interventional study of Atovaquone in Pneumonia, Pneumocystis Carinii and HIV Infections, sponsored by Glaxo Wellcome. Completed at 1 site in United States. Open to participants aged 1 Day and older. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by Glaxo Wellcome · Not applicable, Interventional, and Treatment
To facilitate provision of atovaquone (566C80) to patients who have severe Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole ( TMX / SMX ); to monitor serious adverse events attributable to 566C80.
2,044 studies on the registry are indexed under Pneumonia; 283 are open to participants now.
Browse Pneumonia studies →Glaxo Wellcome is the lead sponsor of 72 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients must have the following:
Exclusion Criteria
Co-existing Condition:
Excluded:
Required:
This study is completed, as verified in Apr 1993. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Glaxo Wellcome